Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DENOCHARCOT trial
2018-003724-36Phase 3Active
- Sponsor
- Ole Lander Svendsen
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Charcot arthropathy (CN), Charcot neuroarthropathy (CN) and type 2 diabetes mellitus (T2DM) comparing Prolia with Placebo (2 arms). Primary endpoint: Time to clinical healing/remission of acute Charcot foot. Started Dec 2019; status: active.
02
Drugs
denosumab
03
Conditions
Charcot arthropathy (CN)Charcot neuroarthropathy (CN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2018-003724-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003724-36.